TELA Bio (TELA)
(Real Time Quote from BATS)
$6.44 USD
+0.16 (2.55%)
Updated May 20, 2024 01:10 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TELA 6.44 +0.16(2.55%)
Will TELA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TELA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TELA
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
TELA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
Other News for TELA
TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tela Bio price target lowered by $2 at Piper Sandler, here's why
TELA Bio’s Robust Growth and Promising Outlook Merit Bullish Stance